OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.4067) per share and revenue of $0.17 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.23. On average, analysts expect OnKure Therapeutics to post ($1.47) EPS for the current fiscal year and ($1.15) EPS for the next fiscal year.
OnKure Therapeutics Stock Down 3.5%
Shares of OKUR stock opened at $2.50 on Wednesday. OnKure Therapeutics has a 52 week low of $2.01 and a 52 week high of $5.38. The company has a 50-day simple moving average of $2.85 and a 200 day simple moving average of $3.59.
Analysts Set New Price Targets
Several equities research analysts have issued reports on the stock. HC Wainwright cut their price objective on shares of OnKure Therapeutics to $21.00 and set a “buy” rating for the company in a research report on Monday, July 20th. Weiss Ratings raised OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. Finally, Oppenheimer reiterated an “outperform” rating and set a $14.00 target price on shares of OnKure Therapeutics in a research note on Friday, August 14th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, OnKure Therapeutics currently has an average rating of “Hold” and a consensus target price of $17.50.
Get Our Latest Stock Analysis on OKUR
About OnKure Therapeutics
OnKure Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company’s research is centered on small-molecule therapies designed to target cancer-driving transcription factors and related proteins that are difficult to address with conventional drug approaches.
Its lead product candidate, OKN4395, is an oral small-molecule inhibitor of the EP300/CBP bromodomains. The program is being investigated as a potential treatment for solid tumors, including in combination with immune checkpoint inhibitors such as pembrolizumab.
Featured Stories
- Five stocks we like better than OnKure Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
